Employees: 807
Size Hangzhou AGS MedTech (688581.SS) is a China Health Care company (Medical Specialties) with a market value of $590M, the 3292nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥48.88 on 18 Nov 2026.
Performance Over six months the shares fell 21.9%, against -2.1% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 19 in its peer set.
Growth Revenue fell 18.1% over the last twelve months (peer median +14.4%); the operating margin is 32.6% (peer median 7.4%).
Valuation It trades at 18.9× forward earnings against a peer median of 27.7× (4th cheapest of 11).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -27 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.5 points above its cost of capital (7.8% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥548M | CN¥587M | CN¥630M | CN¥505M | CN¥368M |
| Revenue growth | — | -7% | +25% | +37% | — |
| Gross profit | CN¥395M | CN¥405M | CN¥447M | CN¥354M | CN¥247M |
| EBITDA | n/a | CN¥226M | CN¥292M | CN¥223M | CN¥157M |
| Net income | CN¥188M | CN¥222M | CN¥293M | CN¥217M | CN¥145M |
| Free cash flow | CN¥146M | CN¥87.7M | CN¥266M | CN¥170M | CN¥96.3M |
| Capital expenditure | CN¥55.4M | CN¥63.5M | CN¥49.6M | CN¥51.6M | CN¥60.1M |
| Total debt | CN¥72.4M | CN¥54.9M | CN¥10.6M | CN¥11.9M | CN¥6.71M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688581.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.2% | -0.8% | 5th lowest of 19 |
| 6-month return | -21.9% | -2.1% | 8th lowest of 19 |
| Distance from 52-week high | -34.3% | -32.7% | 10th lowest of 20 |
| Revenue growth (TTM) | -18.1% | +14.4% | lowest of 20 |
| Operating margin | 32.6% | 7.4% | 2nd highest of 20 |
| Forward P/E | 18.9× | 27.7× | 4th cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | 0.4% | 8.4% | 5th least demanding of 10 |
| Growth delivered (Del g) | +27.8% | +6.7% | 2nd highest of 10 |
| Hurdle (Req g minus delivered) | -27.5 pp | -3.6 pp | least demanding of 10 |
| ROIC minus cost of capital | +13.5 pp | -3.3 pp | 5th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 18.9× | 0.4% | +27.8% |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 12.0× | n/a | n/a |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 21.1× | 8.4% | +12.0% |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | n/a | n/a | n/a |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | n/a | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |
| Sight Sciences SGHT | United States | $599M | +122% | +16% | -30% | n/a | n/a | n/a |
| Medistim MEDI.OL | Norway | $599M | +32% | +19% | 29% | 31.8× | -1.2% | +14.5% |
| Nanosonics NAN.AX | Australia | $599M | -4% | +3% | 7% | 98.6× | 35.3% | +6.7% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 39.7× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | n/a | n/a | n/a |
| Xvivo Perfusion XVIVO.ST | Sweden | $611M | -32% | +18% | 12% | 53.1× | 35.9% | +35.2% |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 33.7× | n/a | n/a |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $618M | -27% | -13% | 31% | 17.4× | -8.5% | +2.2% |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | n/a | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $630M | 0% | +19% | 51% | n/a | -2.6% | +18.8% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | n/a | 15.0% | -19.8% |
| AK Medical 1789.HK | Hong Kong | $642M | -23% | +16% | 26% | 10.5× | -11.5% | +6.7% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 23.5× | 10.2% | +6.5% |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | n/a | n/a | n/a |